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We describe an outbreak of Pneumocystis jirovecii
pneumonia in a pediatric renal transplant unit, likely attrib-
utable to patient-to-patient transmission. Single-strand con-
formation polymorphism molecular typing showed that 3
affected patients had acquired the same 2 strains of
Pneumocystis, which suggests interhuman infection. An
infant with mitochondriopathy was the probable index
patient.
D
espite intensive medical treatment, Pneumocystis
jirovecii pneumonia (PCP) is still a severe disease in
immunocompromised patients, with a high death rate of
up to 50 % (1). The first report of human Pneumocystis
infection appeared in 1909; nevertheless, its epidemiology
is poorly understood to date. In the 1950s, reports on PCP
epidemics in malnourished infants in hospitals and orphan-
ages aroused suspicion of interhuman transmission. In
addition, animal studies have demonstrated airborne trans-
mission of Pneumocystis (2). A case-control study con-
ducted for a cluster of 5 PCP cases in transplant recipients
suggested transmission of P. jirovecii from AIDS patients
to other immunosuppressed persons (3). However, molec-
ular typing methods for P. jirovecii were lacking so that
patient-to-patient transmission could not be assessed at the
molecular level. When such techniques were developed in
the 1990s, 3 analyses showed different P. jirovecii geno-
types within clusters (4–6). Arecent analysis at the molec-
ular level of a cluster of 10 PCP cases strongly suggested
that HIV-infected persons with active PCP transmitted P.
jirovecii to renal transplant recipients (7). The role of inter-
human transmission of P. jirovecii in the epidemiology of
PCP is still unclear.
The Outbreak
Having observed no occurrence of PCP in our pediatric
renal transplant unit for the last 20 years and only 1 case in
all German pediatric renal transplant units during the last
10 years, we encountered 3 consecutive incidents of PCP
during a 5-month period. The first patient was a 13-year-
old girl, who had received her second renal graft because
of cystic kidney disease; PCP developed 4 months after
transplantation. The second patient, a 14-year-old boy, fell
ill in the ninth posttransplant month; he had bilateral vesi-
coureteral reflux as underlying renal disease. The third
patient was a 13-year-old girl, who had a transplant 2 years
before contracting PCP because of cystic renal dysplasia
occurring in the context of Bardet-Biedl syndrome.
All 3 children had been given cyclosporine A (average
dose 6.7 mg/kg/day), mycophenolate mofetil (1,060
mg/m2/day), and methylprednisolone (3.2 mg/m2/day), as
maintenance immunosuppression. One patient had also
received induction therapy with the interleukin-2-receptor-
antibody basiliximab. All 3 children had been treated with
methylprednisolone pulses for acute rejection episodes 2,
3, and 15 months before PCP was diagnosed. 
Clinically, all patients showed nonspecific symptoms,
such as mild fever, dyspnea, and dry cough in the absence
of auscultatoric anomalies. Laboratory tests showed an
elevation of lactic dehydrogenase activity, C-reactive pro-
tein concentration in blood, and pronounced hypercal-
cemia (2.7–3.5 mmol/L), which was interpreted as an
extrarenal production of 1.25-dihydroxyvitamin D3 by
activated alveolar macrophages. We found a significant
reduction of S-adenosylmethionine concentration in plas-
ma (6 nmol/L; normal range 86–128 nmol/L), which
appears to be specific to PCP, unlike bacterial or other
atypical pneumonias (8). We measured the blood count of
CD4+ and CD4/DR+T lymphocytes in the third patient to
indicate the degree of immunosuppression, since antirejec-
tion therapy had been administered 15 months before the
occurrence of PCP. The number of CD4+T cells was nor-
mal at the time of PCP diagnosis (1,100 cells/µL; normal
range 505–1,151 cells/µL), while the number of activated
T-helper cells was slightly decreased (24 CD4/DR+
cells/µL; normal range 29–87/µL). Only in the course of
PCP did the numbers of CD4+- and CD4/DR+-T lympho-
cytes drop significantly (308 CD4+-T cells/µL and 8
CD4/DR+ cells/µL). Chest radiographs and thorax comput-
ed tomographic scans of the 3 children showed typical
signs of interstitial pneumonia, e.g., ground-glass opacity.
Diagnosis of PCP was confirmed by the presence of
cysts and vegetative forms in bronchoalveolar lavage fluid,
proved by immunofluorescence staining, and through
detection of Pneumocystis DNA by means of polymerase
chain reaction (PCR). In spite of intensive antimicrobial
therapy, 2 of our 3 renal transplant patients died, at 10 and
28 days, respectively, after the onset of PCP.
To determine if PCPcould have been caused by patient-
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PCP in the infected children (Figure). Patient 1 stayed on
the same ward and same floor, but not in the same room
(distance between the rooms’ doors ≈10 m), as an infant
with a yet-unclassified mitochondriopathy and pneumonia,
which later was diagnosed as PCP. Patient 2’s hospital stay
overlapped that of patient 1; the patients were on the same
ward and same floor, in rooms with doors separated by 8
m, before the onset of PCP. Patient 3 spent her holiday
with patient 2 in a summer camp organized by our
Pediatric Nephrology Division.
Proceeding on the assumption that PCP in the 4 chil-
dren resulted from patient-to-patient transmission, we
investigated the genotypes of P. jirovecii with the multitar-
get single-strand conformation polymorphism (SSCP)
method. This typing procedure is based on the amplifica-
tion by PCR of 4 variable regions of the genome, followed
by the detection of polymorphisms by means of SSCP.
These 4 genomic regions are as follows: internal tran-
scribed spacer number 1 of the nuclear rRNA genes oper-
on (ITS1), the intron of the nuclear 26S rRNA gene (26S),
the variable region of the mitochondrial 26S rRNA gene
(mt26S), and the region surrounding intron number 6 of
the β-tubulin gene (β-tub). Typing procedures were carried
out as described elsewhere (9). Avariable region amplified
from a bronchoalveolar lavage fluid specimen can gener-
ate either 2 bands (simple pattern) or >2 bands (complex
pattern). While a simple pattern corresponds to a single
allele of the genomic region, the presence of >2 bands
(complex pattern) indicates the existence of several alleles
for a given region, most probably attributable to coinfec-
tion with multiple P. jirovecii types(10).
Our analysis showed that all 3 renal transplant patients
had acquired the same 2 strains of Pneumocystis, types 1
and 2. The infant with mitochondriopathy had been infect-
ed with >2 strains, which possibly included types 1 and 2
(Table). In contrast, 3 unrelated cases in patients (patients
4, 5, and 6) from the same hospital harbored other P.
jirovecii types. The index of discrimination of the method
was high (0.93) (10), and the probability that patients 1, 2,
and 3 were infected with the same strains by chance is
extremely low. We observed that the proportion of coin-
fecting strains within the clinical specimen was more
important than the amount of template DNA to detect or
not detect a strain by means of the SSCP typing method. A
coinfecting strain has to represent 11% of the population to
be detected (11). Coinfecting strains are missed when very
low amounts of template DNAare used, sometimes result-
ing in a negative PCR; however, this was not the case for
the specimens analyzed in the present study. 
The index patient had more strains than the other
patients (Table) but generated smaller amounts of PCR
products with the 4 different PCR tests used, which sug-
gests a lower amount of DNA template. Although exclud-
ing a common source of P. jirovecii is difficult, the results
strongly suggest that all 3 kidney transplant recipients had
infected each other, and the infant could have acted as
index patient. This transmission may have occurred direct-
ly from 1 patient to another but also indirectly through
immunocompetent carriers. Indeed, carriage of P. jirovecii
DNA in the nose of immunocompetent relatives and
healthcare workers in close contact with a PCP patient has
been described (12).
Conclusions
To our knowledge, this report is the first published on
an outbreak of PCP in a pediatric renal transplant unit,
probably attributable to patient-to-patient transmission.
However, we cannot exclude that the cases described were
infected by the same environmental source. The presence
of  P. jirovecii in the air of hospital corridors has been
described (13), making an environmental reservoir in the
hospital possible. Other potential sources of P. jirovecii
could be asymptomatic P. jirovecii carriers, such as
immunosuppressed patients (14,15). Our findings at the
molecular level suggest that P. jirovecii may be transmitted
nosocomially and be acquired by immunosuppressed pedi-
atric transplant recipients. The incubation periods of P.
jirovecii infection (17, 15, and 19 weeks for patients 1, 2,
and 3, respectively) would be longer than those (2–12
weeks) suggested by the previously described clusters of
PCP (3,7,16). This finding may reflect a difference
between adults and children.
Until the outbreak of PCP outlined in this article, pedi-
atric renal transplant recipients in our hospital and other
pediatric renal transplant units in Germany were not given
PCP prophylaxis routinely because of possible side effects,
such as a rise of serum creatinine values, myelosuppression,
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Figure. Course of Pneumocystis
pneumonia (PCP) in 3 pediatric renal
transplant recipients and 1 infant suf-
fering from a yet-unclassified mito-
chondriopathy. R, acute rejection
episode; RTx, renal transplantation;
↓, contact; #, joint holiday;  > start of
PCP symptoms;  – , hospitalization;
X, diagnosis of PCP; D, death.and Lyell syndrome. We had not observed any case of PCP
in our transplant recipients for the last 20 years without
prophylaxis. In the light of the high death rate for PCP,
prophylactic treatment with trimethoprim-sulfamethoxa-
zole is highly recommended for the first 6 posttransplant
months and during the 4 months after antirejection thera-
py, in accordance with the guidelines for adults (1).
According to these guidelines, patient 3, in whom PCP
developed 15 months after steroid pulse therapy, would not
have been protected by prophylaxis. Whether prophylaxis
should be given for a longer period of time remains
unknown, particularly since immunosuppression did not
appear to be intensive in this patient at the onset of PCP, as
indicated by the normal CD4+ T-lymphocyte count in
peripheral blood and the only slightly decreased number of
activated T-helper cells. 
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